The objective of the Top Ten Trials session is to provide a multidisciplinary audience with a snapshot of the two most influential trials from each discipline within the past year. The selected trials will generally address important areas of cardiology and may influence clinical practice and inform future clinical guidelines. Usual format is a general presentation of the finding of the study by the Trial Presenter and then a deep dive of the data and relevance of that study by the Trial Discussant. The discussant in each discipline is asked to critically appraise the trials in the context of existing evidence. The discussant should also inform the audience how the trials might change perspective within the discipline or influence wider clinical practice. Chairs Dr. Muram El-Nayir Dr. Rosita Zakeri Presenter/Discussant Trial Presenter 1: Dr. Jennie Han - REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced EF Trial Discussant 1: Dr. Ali Vazir - REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced EF Trial Presenter 2: Dr. Oliver Harrison - ODYSSEY-HCM: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Trial Discussant 2: Dr. Katie Linden - ODYSSEY-HCM: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Trial Presenter 3: Dr. Shruti Joshi - CLOSURE-AF & Champion-AF: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (CLOSURE-AF), Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION- AF) Trial Discussant 3: Dr. Rohan Wijesurendra - CLOSURE-AF & Champion-AF: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (CLOSURE-AF), Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION- AF) Trial Presenter 4: Dr. Magda Klis - AMALFI: Remote Screening for Asymptomatic Atrial Fibrillation Trial Discussant 4: Dr. Jane Caldwell - AMALFI: Remote Screening for Asymptomatic Atrial Fibrillation Trial Presenter 5: Dr. Ahmed Abdelrazik - WITHDRAW-AF: Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalisation Trial Discussant 5: Dr. Jessica Webb - WITHDRAW-AF: Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalisation